高剂量与标准剂量流感疫苗在美国老年医保人群中预防可能流感的相对疫苗效果
本研究基于美国Medicare按服务收费参保者,在2011-2012至2014-2015四个流感季节比较高剂量与标准剂量流感疫苗的真实世界相对疫苗效果。高剂量组与标准剂量组按地点、接种日期、年龄和性别1:1匹配,采用Fine-Gray竞争风险模型调整残余混杂。结果显示高剂量疫苗在流感高峰季对可能流感的保护 consistently 优于标准剂量,但门诊接种队列中效果较低,可能反映医生将高剂量疫苗分配给更虚弱患者的偏倚。
要点
- 高剂量流感疫苗在四个流感季节中与更好的可能流感保护相关。
- 药房队列高峰季相对疫苗效果为14.8%至21.8%,门诊队列为-0.2%至16.5%。
- 门诊队列效果较低可能反映医生将高剂量疫苗分给更虚弱患者的偏倚。
核心结论
- 高剂量流感疫苗在四个流感季节中与更好的可能流感保护 consistently 相关。
- 门诊接种队列中观察到的较低治疗效果可能反映医生将高剂量疫苗分配给更虚弱患者的偏倚。
研究设计与样本
- 研究纳入2011-2012至2014-2015流感季节期间在门诊诊所或药房接种高剂量或标准剂量流感疫苗的Medicare按服务收费参保者。
- 高剂量接种者与标准剂量接种者按地点、接种日期、年龄和性别进行1:1匹配。
- 采用Fine-Gray竞争风险模型(考虑死亡竞争风险)调整残余混杂,并按门诊接种与药房接种分层分析。
主要发现
- 四个流感季节中,药房队列的样本量分别为535,598、1,017,552、1,548,164和2,420,450;门诊队列分别为821,662、1,151,080、1,559,488和2,421,758。
临床怎么用
- 在老年人群中,高剂量流感疫苗可能提供比标准剂量更好的可能流感保护,尤其药房接种场景下效果较为一致。
- 门诊接种场景下效果估计可能受适应症混杂影响,解读时应考虑接种者的虚弱程度差异。
局限性
- 研究为观察性设计,尽管采用匹配和竞争风险模型调整,仍可能存在残余混杂。
- 门诊队列中医生可能将高剂量疫苗优先分配给更虚弱患者,导致治疗效果被低估。
- 结果基于Medicare按服务收费人群,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose (HD) influenza vaccine, currently the most commonly used vaccine among US seniors (aged ≥ 65 years), has been shown to be more efficacious than standard-dose (SD) vaccine in multiple randomized trials. This study evaluated the real-world relative vaccine effectiveness (rVE) of HD vs SD over four influenza seasons. METHODS: This study included Medicare Fee-for-Service enrollees who received HD or SD at an outpatient clinic or pharmacy during influenza seasons 2011-2012 through 2014-2015. Probable influenza (an inpatient stay with an influenza diagnosis on the claim, or an outpatient visit with a rapid influenza test/culture followed by an antiviral prescription) was assessed among HD recipients matched 1:1 with SD recipients by location, vaccination date, age, and sex. Fine-Gray subdistribution hazard models with competing risk of death were used to adjust for residual confounding. Analyses were stratified by outpatient vs pharmacy vaccination. RESULTS: Across the four influenza seasons, there were 535,598, 1,017,552, 1,548,164, and 2,420,450 in the pharmacy cohort; and 821,662, 1,151,080, 1,559,488, and 2,421,758 in the outpatient cohort. During peak influenza season, rVEs for 2011-12 through 2014-15 were 21.8% (95% CI: -5.9%, 42.3%), 14.8% (9.3%, 19.9%), 16.9% (9.2%, 23.9%), and 17.2% (14.5%, 19.9%), respectively, in the pharmacy cohort; and 16.5% (-5.9%, 34.2%), 15.1% (10.9%, 19.1%), 10.0% (2.9%, 16.6%), and -0.2% (-3.0%, 2.5%), respectively, in the outpatient cohort. CONCLUSION: HD was consistently associated with better protection against probable influenza. The lower treatment effect observed in the outpatient cohort could reflect provider bias due to physicians triaging HD to frailer patients.
引用
- Paudel M, Mahmud S, Buikema A, et al. Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population. Vaccine. 2020. PMID: 32446835. doi:10.1016/j.vaccine.2020.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。